glp 1 reducing inflammation The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury Glucagon-like peptide-1 receptor: mechanisms and

Diabetes is prevalent worldwide and the number of patients is drastically rising, with a predication of 366 million in 2030 due to factors such as obesity, inactivity,

Growing evidence suggests that GLP-1 receptor agonists like semaglutide may offer unexpected benefits beyond weight loss, including potential migraine relief through metabolic and inflammatory pathways

lactis B420, an exclusive strain clinically studied for women over 50 and during menopause

Health Canada authorizes injection for treatment of adult patients with type 2 diabetes

Had missed this detail @Humana was selected by CMS as the central processor for the Medicare GLP-1 Bridge Makes sense given Humana already administers prescription drug access for the LI NET program

Tirzepatide Cuts Risk of Diabetes by 94% in Prediabetic Adults